

# Gemini Stock Analysis Report

---

Based on the detailed analysis report for **DIVISLAB.NS** (generated date: 2026-01-24), here is the assessment from the perspective of a risk-averse positional trader.

## Step 1: Audit the Data

- **Data Present:**

- **Price Action:** High-quality Daily, Weekly, and 15-min charts (Candlestick & Line).
- **Trend Indicators:** Moving Averages (EMA 20, 50, 200), Supertrend, MACD.
- **Oscillators:** RSI (Relative Strength Index), Bollinger Bands.
- **Fundamentals:** 4-year long-term view and 6-quarter short-term view.
- **Volume:** Volume bars with moving averages and distribution day analysis.
- **Relative Strength:** RS Score and comparison vs. Benchmark (^CNXPHARMA).

- **Data Missing:**

- **Specific News Context:** While price action reflects sentiment, the report does not specify the fundamental catalyst for the recent sharp drop (e.g., FDA observation, earnings miss).
- **Sector Breadth:** Broader Pharma sector health is implied but not explicitly detailed beyond the RS comparison.
- **Confidence Level: High.** The technical data is comprehensive enough to make a sound decision based on price structure and trend.

---

## Step 2: Analyze the Setup

- **Price Structure (Bearish):** The stock has suffered a significant breakdown. As seen on **Page 7**, the price (6011) is trading below the **EMA 200 (6239)**, **EMA 50 (6362)**, and **EMA 20 (6280)**.

- **Trend Direction (Negative):**

- **Moving Averages:** A "Death Cross" scenario is unfolding where short-term averages (20/50) are crossing below the long-term average (200).
- **Supertrend:** Page 10 confirms a **DOWNTREND (Sell)** signal active since 2026-01-16 with trailing resistance at 6454.
- **Multi-Timeframe:** Page 20 confirms the stock is in a downtrend on Weekly, Daily, and 15-min timeframes.

- **Momentum (Weak):**

- **RSI:** At **31.12** (Page 16), the stock is oversold. While this often invites a bounce, in a strong downtrend, "oversold" can persist for extended periods.
- **MACD:** The MACD is bearish, below the signal line, and momentum is weakening.

- **Fundamentals (Deteriorating):** Page 3 indicates recent Quarter-over-Quarter weakness, with Revenue down -5.49% and Net Income down -17.67%. This fundamental weakness aligns with the technical breakdown.

**Confluence Check:** There is currently **zero confluence** for a long position. The trend, momentum, relative strength (RS Score 48.8), and fundamentals are all aligned to the downside.

---

## Step 3: Formulate the Recommendation

**Recommendation: NO / AVOID**

**Reasoning:** Entering a long position now would be "catching a falling knife." The stock is in a **Stage 4** decline (markdown phase). It is trading below the 200-day moving average, has heavy institutional distribution

# Gemini Stock Analysis Report

---

(selling), and has broken key support levels. The probability of a sustainable 5-15% upside move is low until the structural damage is repaired.

## Conditional Plan (Watchlist for Reversal)

We require the stock to stop making lower lows and reclaim key institutional levels before considering an entry.

- **Condition to Buy:** The stock must close significantly above the **Supertrend Resistance** and the **EMA 50** to prove the downtrend is broken.
- **Entry Price: INR 6,460** (Daily Close basis).
  - *Logic:* This level clears the current Supertrend sell signal (6454) and the EMA 50 (6362), putting the price back above the crucial EMA 200 zone.
- **Stop Loss: INR 6,150** (Hard Stop).
  - *Logic:* If it breaks back below the EMA 200/EMA 20 zone after breakout, the setup has failed.
- **Take Profit: INR 6,950 - INR 7,000.**
  - *Logic:* This targets the previous swing highs and liquidity zone established in late 2025.

**Current Action:** Remove from active trade list. Set an alert at **INR 6,250** to begin monitoring for a potential bottoming formation.

## News & Analyst Targets

As a stock research analyst, I have compiled the latest news, brokerage views, and market intelligence for **Divi's Laboratories (DIVISLAB)** for the week ending **January 25, 2026**.

### 1) Latest News for DIVISLAB (Week of Jan 19-25, 2026)

- **Significant Surge in Open Interest:** On **January 22, 2026**, the stock witnessed a sharp **12.5% increase in Open Interest (OI)** in the derivatives segment. This huge spike, accompanied by high volumes, indicates that large positions are being built ahead of the upcoming earnings, signaling potential volatility.
- **Price Under Pressure:** The stock has been technically weak this week, trading below key moving averages (20, 50, and 200-day). It closed the week on a negative note, down approximately **3.6%**, reflecting caution among traders.
- **Earnings Date & Trading Window:** The company has confirmed that the **trading window remains closed** effective January 1, 2026. The Q3 FY26 earnings results are tentatively expected to be announced around **February 4, 2026**.
- **Technical Downgrade:** On **January 16, 2026**, research firm **MarketsMojo** downgraded the stock from "Hold" to "**Sell**", citing deteriorating technical indicators and valuation concerns.

### 2) Brokerage Upgrades & Downgrades

The analyst community is currently divided, with foreign brokerages generally more bullish on the long-term "China Plus One" story, while some domestic firms remain cautious due to valuation.

- **Citi (Bullish):** In a note dated **January 6, 2026**, Citi maintained a "**Buy**" rating with a street-high target of **INR 9,140**. They remain positive on Divi's strong custom synthesis pipeline and potential gains from GLP-1 (weight loss drug) intermediates.
- **Jefferies (Bullish):** Continues to hold a "**Buy**" rating (reiterated late 2025) with a target of **INR 7,850**, driven by the recovery in the custom synthesis segment and new project commercialization.
- **ICICI Securities (Bearish):** Maintains a "**Sell**" rating with a significantly lower target of **INR 4,500**, citing

# Gemini Stock Analysis Report

rich valuations that may already price in near-term growth recovery.

- **MarketsMojo (Bearish):** Downgraded to "Sell" this week due to negative technical momentum.

## 3) Other News Impacting DIVISLAB (Indirect & Sectoral)

- **US Biosecure Act (Positive Structural Tailwind):** The US Senate's recent moves to advance the **Biosecure Act** (aimed at restricting US federal contracts with certain Chinese biotech firms) is a major positive. As a leading CDMO (Contract Development and Manufacturing Organization), Divi's Lab is a primary beneficiary as global pharma giants look to diversify supply chains away from China.
- **Regulatory Environment (Neutral/Caution):** The US FDA remains active in India. This week, competitor **Zydus Lifesciences** completed an inspection with 3 observations, while **Cipla** faced supply issues due to FDA observations at a partner's site. This highlights the continued need for strict compliance, though Divi's has historically had a clean track record.
- **GLP-1 "Weight Loss" Drug Boom:** Competitors like **Sun Pharma** and **Dr. Reddy's** made headlines this week for advancing their generic Semaglutide (weight loss drug) plans. This is relevant for Divi's because it is a key supplier of **peptide building blocks** used in these drugs. The aggressive expansion of this market is a direct revenue driver for Divi's custom synthesis business.

## 4) Analyst Price Targets (January 2026)

Below is a summary of the latest available targets from major brokerage houses and consensus data.

Brokerage / Firm	Rating	Target Price (INR )	Upside/Downside*	View / Rationale
Citi	Buy	9,140	+52%	Top pick for CDMO recovery & GLP-1 opportunities.
Jefferies	Buy	7,850	+30%	Strong custom synthesis growth & margin expansion.
Sharekhan	Buy	7,100	+18%	Long-term export growth visibility.
Trendlyne Consensus	Hold	6,823	+13%	Average of all active analyst coverage.
Motilal Oswal	Neutral	6,320	+5%	Valuation is fair; waiting for consistent earnings beat.
ICICI Securities	Sell	4,500	-25%	Valuations are expensive; risk-reward is unfavorable.

\*Upside/Downside calculated based on the approximate closing price of INR 6,011 as of Jan 23, 2026.

**Analyst Summary:** The stock is currently trading in a "tug-of-war" zone. While the **long-term structural story** (China Plus One, GLP-1 opportunity) keeps foreign analysts highly bullish (targets >INR 7,500), **short-term technicals and valuation concerns** have led to caution from some domestic desks. The upcoming Q3 earnings in early February will likely be the decisive trigger for the next major move.


# Stock Detailed Analysis Report

**DIVISLAB.NS**

Current Price: ₹6011.50

Generated: 2026-01-24 18:27

# DIVISLAB.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	19.61%	1.95%
Net Income	No	Yes	36.94%	-9.55%
ROE	No	Yes	24.15%	-16.61%
EPS	No	Yes	36.93%	-9.55%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-5.49%	3.51%
Net Income	Yes	-17.67%	7.20%
ROE	Yes	18.95%	18.95%
EPS	Yes	15.62%	17.07%

# DIVISLAB.NS - Relative Strength Analysis

## == OVERVIEW ==:

**Benchmark Index:** ^CNXPHARMA

**Sector:** Pharma

**Classification:** Neutral

**RS Score:** 48.8/100

:

## == RS RATIOS ==:

**1M RS:** 0.977 [Neutral]

**3M RS:** 0.968 [Neutral]

**6M RS:** 0.942 [Neutral]

**1Y RS:** 1.051 [Leader]

:

## == TURNAROUND ANALYSIS ==:

**Turnaround Status:** !! DETECTED !!

:


## SIGNAL CRITERIA::

✓ **Emerging RS:** 1M (0.977) > 3M (0.968)


✓ **Medium-term Lagging:** 6M=0.942 ( $\leq 1.0$ )

✓ **Performance Improving:** 3M (-8.4%) > 6M (-8.7%)


**Relative Strength Analysis: DIVISLAB.NS vs ^CNXPHARMA**  
**Classification: Neutral**  
**Price Performance Comparison (Normalized)**



**RS Ratio Trends (Multiple Timeframes)**




**RS Composite Score Timeline**



## DIVISLAB.NS - EMA Crossover Summary

<b>EMA 20:</b>	6280.48
<b>EMA 50:</b>	6362.66
<b>EMA 200:</b>	6239.98
<b>Trend Status:</b>	<b>Short-term Downtrend</b>
<b>Golden Cross Date:</b>	2024-04-09 00:00:00+05:30
<b>Golden Cross Price:</b>	3764.60

# DIVISLAB.NS EMA Crossover Analysis



## DIVISLAB.NS - Bollinger Bands Summary

<b>Current Price:</b>	6011.50
<b>Upper Band:</b>	6756.99
<b>Middle Band (SMA 20):</b>	6343.00
<b>Lower Band:</b>	5929.01
<b>%B:</b>	0.0996
<b>Band Width:</b>	0.1305
<b>Status:</b>	Lower Half
<b>Signal:</b>	None

## DIVISLAB.NS Bollinger Bands (20, 2) Analysis




## **DIVISLAB.NS - Supertrend Summary**

**Status:** DOWNTREND (Sell)

**Supertrend Value:** 6454.14

**Signal Identified On:** 2026-01-16

### SuperTrend Analysis for DIVISLAB.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## DIVISLAB.NS - MACD Summary

<b>MACD Line:</b>	-104.77
<b>Signal Line:</b>	-53.56
<b>Histogram:</b>	-51.21
<b>Trend:</b>	<b>Bearish</b>
<b>Momentum:</b>	<b>Weakening</b>
<b>Signal:</b>	None

### DIVISLAB.NS Price






### DIVISLAB.NS MACD (12, 26, 9)



## DIVISLAB.NS - Volatility Squeeze Summary

<b>BB Width:</b>	0.1305
<b>ATR:</b>	151.7143
<b>Total Signals:</b>	31
<b>Signal 1:</b>	BB Squeeze at 2025-12-30 00:00:00+05:30 (Price: 6360.50)
<b>Signal 2:</b>	BB Squeeze at 2025-12-31 00:00:00+05:30 (Price: 6392.50)
<b>Signal 3:</b>	BB Squeeze at 2026-01-01 00:00:00+05:30 (Price: 6344.00)
<b>Signal 4:</b>	BB Squeeze at 2026-01-02 00:00:00+05:30 (Price: 6392.50)
<b>Signal 5:</b>	BB Squeeze at 2026-01-05 00:00:00+05:30 (Price: 6363.50)




## DIVISLAB.NS - Volatility Squeeze Analysis



## DIVISLAB.NS - RSI-Volume Summary

<b>Current RSI:</b>	31.12
<b>Current Volume:</b>	460503
<b>Volume MA 20:</b>	412605
<b>Bullish Divergences:</b>	1
<b>Bearish Divergences:</b>	1
<b>Bullish Div 1:</b>	Date: 2025-12-17 00:00:00+05:30, Price: 6293.00
<b>Bearish Div 1:</b>	Date: 2024-07-10 00:00:00+05:30, Price: 4587.77

## DIVISLAB.NS RSI-Volume Divergence Analysis



# **DIVISLAB.NS - Volume Analysis**

## **== VOLUME ANALYSIS ==:**

**Status:** 33 Signals Detected

:



**2025-12-29 [-]:** Distribution Day

**2025-12-30 [-]:** Distribution Day

**2026-01-14 [-]:** Distribution Day

**2026-01-23 [-]:** Distribution Day

## DIVISLAB.NS - Volume Analysis



## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	6695.25	6011.5	2026-01-19
1 Day	DOWNTREND (Sell)	6454.14	6011.5	2026-01-16
15 Min	DOWNTREND (Sell)	6069.43	6011.5	2026-01-23

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Strengthening	No Signal
1 Day	Bearish	Weakening	No Signal
15 Min	Bearish	Weakening	No Signal

### DIVISLAB.NS - 1 Week (Candlestick + EMAs)



### DIVISLAB.NS - 1 Day (Candlestick + EMAs)



### DIVISLAB.NS - 15 Min (Candlestick + EMAs)



# Trendlyne Snapshot - DIVISLAB\_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More ▾

Search Stock, IPO, MF A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [DIVI'S LABORATORIES LTD.](#)

## Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488  
Divi's Laboratories Live Share Price Today, Share Analysis and Chart

Expensive Performer In 1 Starfolio Basket

**6011.50** -59.50 (-0.98%)

**463.7K** NSE+BSE Volume  
NSE 23 Jan, 2026 3:31 PM (IST)

**TRADE STOCK**

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

Durability score <b>70.0 /100</b> High Financial Strength	Valuation Score <b>26.0 /100</b> Expensive Valuation	Momentum Score <b>42.1 /100</b> Technically Neutral	Analyst Price Target <b>6,823</b> 1Yr Price target upside is 14%	<a href="#">FORECASTER</a>
--	---	--	---	----------------------------

**Expensive Performer** These stocks are strong in quality but with mid-range technicals. Their valuations are expensive

**View Similar** Embed DVM

**Check Before You Buy** [VIEW FULL CHECKLIST](#)  
High rank 13 10  
3 2   
Positive 14 \* 9 Negative  
60.9% Pass in checklist

**PE Valuation Check**  
Right Now Overvalued -5.1%  
1 Year Forward Fairly Valued -1.3%

**IN SIGHT** Divi's Laboratories is overvalued at current PE, but fairly valued on future earnings

**Divi's Laboratories Key Metrics**

ROE Ann. %  Below Industry Median	Broker Average Target  4.30% upside	6,270	Market Capitalization  Market Runner Up	159,586.4	Price to Book  High in industry
-----------------------------------	-------------------------------------	-------	---	-----------	---------------------------------

**Preset Metrics** **10.4**

DVM  
Key Metrics  
Price Chart  
Forecaster  
Financials  
Technicals  
Shareholding  
Deals  
Documents  
Corporate actions  
Company Profile X

## Trendlyne Snapshot - DIVISLAB\_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [DIVI'S LABORATORIES LTD.](#)

### Divi's Laboratories Ltd. [ⓘ](#)

NSE: DIVISLAB | BSE: 532488  
Expensive Performer [ⓘ](#) In 1 Starfolio Basket

[Download real time STOCK REPORT](#)

**6011.50** -59.50 (-0.98%) **463.7K** NSE+BSE Volume  
NSE 23 Jan, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes [TRADE STOCK](#)


Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News [Reports](#) Technicals Shareholding Deals Corporate Actions Alerts About

### Divi's Laboratories - DIVISLAB - stock price prediction, stock forecast, target price, analyst ratings from 31 analysts

Divi's Laboratories has a share price target of Rs 6823, revenue growth forecast of 14.5%, and profit growth estimate of 18.2% for FY26, based on top 31 analyst calls.

### Divi's Laboratories FORECASTER - Analyst Estimates [ⓘ](#)

[FORECASTER DASHBOARD →](#)



CONSENSUS RECOMMENDATION

31 ANALYST Recommendations

Rating	Count	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26
STRONG BUY	7	4	6	7	4	8	9
BUY	7	5	5	7	5	5	5
HOLD	8	4	5	7	5	6	6
SELL	8	5	5	6	6	6	6
STRONG SELL	8	5	5	6	6	6	6

The consensus recommendation from 31 analysts for Divi's Laboratories is HOLD

● STRONG BUY ● BUY ● HOLD ● SELL ● STRONG SELL